|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0016360,
umls-concept:C0025677,
umls-concept:C0029246,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0035168,
umls-concept:C0036525,
umls-concept:C0087111,
umls-concept:C0205088,
umls-concept:C0205179,
umls-concept:C0239307,
umls-concept:C1274040,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1709059,
umls-concept:C2603343
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1996-9-6
|
|
pubmed:abstractText |
Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer. The European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Cooperative Group (GITCCG) conducted a phase III trial to investigate the efficacy and tolarability of the addition of low-dose MTX (40 mg/m2) to high-dose infusional 5-FU (60 mg/kg over 48 hours) given weekly for 4 weeks and thereafter every 2 (for 4 weeks) and 3 weeks.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BleibergHH,
pubmed-author:BlijhamGG,
pubmed-author:BusetMM,
pubmed-author:CollettiPP,
pubmed-author:DalmarkMM,
pubmed-author:LacaveAA,
pubmed-author:SahmoudTT,
pubmed-author:SelleslagJJ,
pubmed-author:WagenerTT,
pubmed-author:WilkBB,
pubmed-author:de GreveJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2266-73
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8708716-Aged,
pubmed-meshheading:8708716-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8708716-Colorectal Neoplasms,
pubmed-meshheading:8708716-Europe,
pubmed-meshheading:8708716-Female,
pubmed-meshheading:8708716-Fluorouracil,
pubmed-meshheading:8708716-Humans,
pubmed-meshheading:8708716-Infusions, Intravenous,
pubmed-meshheading:8708716-Karnofsky Performance Status,
pubmed-meshheading:8708716-Male,
pubmed-meshheading:8708716-Methotrexate,
pubmed-meshheading:8708716-Middle Aged,
pubmed-meshheading:8708716-Multivariate Analysis,
pubmed-meshheading:8708716-Neoplasm Metastasis,
pubmed-meshheading:8708716-Prognosis,
pubmed-meshheading:8708716-Proportional Hazards Models,
pubmed-meshheading:8708716-Remission Induction,
pubmed-meshheading:8708716-Survival Rate
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
|
|
pubmed:affiliation |
European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group, Brussels, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
